Ongoing Projects

HOME > R&D Pipeline > Current status > Ongoing Projects

KDDF-201809-04 Lead optimization of anti-cancer RNA oligonucleotide inducing immunogenic tumor death(Oncology, Chemical) [2019-07-29]

PRINT
Ongoing Project
Section Lead
Generation
Lead
Optimization
Preclinical Phase I Phase II Phase III

Development and Market Objectives

Development of RNA-based anti-cancer drug that induces immunogenic apoptosis of a tumor by targeting retinoic acid-inducible gene I (RIG-I)

Unmet Medical Need & Target Patients

- Patients with cancers that can be treated by intratumoral injections. However, the indications can be expanded to intravenous injection with further development on the targeted RNA delivery system. It could also be effective against various cancers.  

-  Current immunotherapy of cancer suffers from low response rates possibly due to heterogenetic nature of tumors. There is a growing list of pipelines that exploit novel mechanisms to activate tumor-targeted immunity.

Status

-  Completed total 46 of human and mouse in vitro efficacy test

-  Completed in vivo syngeneic mouse efficacy test (pancreatic, breast, fibrosarcoma cancer)

-  Completed RIG-I mediated Interferon induction test

-  Completed the complex X-ray structure of RIG-I and RNA oligonucleotide in molecular level

-  Developing immunoprofiling test

-  Comparing in vivo efficacy test with competing compound

-  Developing toxicity and PK analysis

Intellectual Property

Total 3 Korea and 1 US patent registration completed and 3 non-provisonal patent applications in Europe, China, Japan.

Competitive Advantages

-  A novel pattern recognition molecular pattern (PAMP) for RIG-I that has not been reported elsewhere.

-  Flexible chemical stability lower the technical barriers in the development process of anti-cancer drugs. 

Contact & Company Overview

Related Project

Related Project
list
Update to 2013 © KOREA DRUG DEVELOPMENT FUND. ALL RIGHTS RESERVED. QR Code